Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Understanding how common fatty liver disease is in patients with Type 1 Diabetes

Official title: The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium

Run by Ziekenhuis Oost-Limburg · NCT06445361 · Data updated 2026-11-12

This study is trying to find out how many people with Type 1 Diabetes also have Nonalcoholic Fatty Liver Disease by using a special scan to check their liver health.

More Type 1 Diabetes trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment138 (estimated)
SponsorZiekenhuis Oost-Limburg
Academic / other
Locations1 site (Genk, Limburg)
StatusRecruiting
StartedJuly 1, 2023
Main results expectedJuly 1, 2026
Study endsJuly 1, 2026
Registry record updatedJuly 28, 2025
Trial IDNCT06445361 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with a diagnosis of Type 1 Diabetes.

Probably not a fit

Patients with excessive alcohol use or other causes of liver disease will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) among patients diagnosed with Type 1 Diabetes Mellitus (T1DM). It involves the use of a FibroScan, a non-invasive imaging technique, to evaluate liver health in participants. The study will include adults aged 18 and older who provide informed consent, while excluding those with excessive alcohol use or other liver disease causes. The findings could provide valuable insights into the liver health of T1DM patients.

Why it matters

Potential benefit: If successful, this study could enhance understanding of liver health in Type 1 Diabetes patients, potentially leading to better management strategies.

How similar studies have gone: While studies on NAFLD in diabetes exist, this specific focus on T1DM patients is less common, making it a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* T1DM
* ≥ 18 years of age
* Written informed consent obtained

Exclusion Criteria:

* Excessive alcohol use
* Exclusion of other causes of liver disease and secondary causes of liver steatosis

Where it's running

  • Ziekenhuis Oost-Limburg
    Genk, Limburg, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.